Research programme: immunostimulatory peptides - SIDR

Drug Profile

Research programme: immunostimulatory peptides - SIDR

Alternative Names: Immunostimulatory peptides research programme - Strathclyde Institute for Drug Research; Immunostimulatory peptides research programme- SIDR; Research programme: immunostimulatory peptides - Strathclyde Institute for Drug Research

Latest Information Update: 27 Apr 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Strathclyde Institute for Drug Research
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Immunodeficiency disorders

Most Recent Events

  • 27 Apr 2001 Discontinued-Preclinical for Immunodeficiency disorders in United Kingdom (Unknown route)
  • 01 Nov 1999 This programme is available for licensing (
  • 20 Jul 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top